본문으로 건너뛰기
← 뒤로

Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.

Cancers 2026 Vol.18(6)

Ren Y, Tang D, Ding X, He M

📝 환자 설명용 한 줄

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, arising from profound metabolic reprogramming and widespread epigenetic dysregulation.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ren Y, Tang D, et al. (2026). Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.. Cancers, 18(6). https://doi.org/10.3390/cancers18061002
MLA Ren Y, et al.. "Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.." Cancers, vol. 18, no. 6, 2026.
PMID 41899603

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, arising from profound metabolic reprogramming and widespread epigenetic dysregulation. However, the role of epigenetic aberrations in modulating metabolic reprogramming and the interplay between -regulatory elements (CREs), such as promoters, enhancers and super-enhancers, and metabolic adaptation have not been systematically summarized. Therefore, this review aims to integrate current evidence to elucidate the mechanisms of how -regulatory elements (CREs) drive oncogenic and metabolic signals in HCC progression. For instance, enhancers and super-enhancers transcriptionally activate key metabolic genes involved in aerobic glycolysis (, , , ), de novo lipogenesis (, , ), glutaminolysis (, ), and nucleotide synthesis. Meanwhile, many metabolic intermediates, including acetyl-CoA, succinyl-CoA and lactate, act as cofactors or substrates for epigenetic modifiers, creating bidirectional feedback loops that reinforce CRE-driven malignant phenotypes. Therefore, aberrant CREs acts as "metabolic switches" that sense and respond to various metabolic conditions to sustain HCC growth. Consequently, targeted intervention against oncogenic CREs, such as super-enhancers or their co-activators, to disrupt CRE-mediated metabolic vulnerabilities, has emerged as a highly promising new paradigm for precision therapy in HCC.

같은 제1저자의 인용 많은 논문 (5)